Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Bausch Health Americas, Inc.
- Enrollment
- 951
- Locations
- 112
- Primary Endpoint
- Overall Responder 9/12 Weeks
Study Overview
Brief Summary
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).
Detailed Description
This is a Phase IIb/III, randomized, double-blind, placebo-controlled, 12-Week, Repeat, Oral Dose Ranging, study to determine the safety and efficacy of plecanatide in patients with chronic idiopathic constipation (CIC). Subjects diagnosed with CIC via modified Rome III criteria will be screened against the inclusion and exclusion criteria for the study and enter a 2 Week pre treatment screening. During this phase patients will be required to call in their bowel movements (BM diary) as they occur, and call at least once daily to complete a patient diary of questions on their symptoms (Symptom Diary) associated with CC, as they will throughout the trial. Patients who complete at least 5 days of dosing per week, 6 of each 7 day period of BM diary calls, and continue to have less than 3 complete spontaneous movements per week (as well as meeting other inclusion and exclusion criteria) will be enrolled and randomized to one of three plecanatide doses 0.3 mg, 1.0 mg, and 3.0 mg or placebo. 880 patients will be randomized with the intent of having 200 patients per treatment group (each group the same size) included in efficacy analyses. All subjects receiving at least one dose of plecanatide or matching placebo will be included in the safety analyses.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female aged 18-75, inclusive
- •Body Mass Index = 18-35 kg/m2, inclusive
- •Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months. Note: For this trial, patients with manual maneuvers required for >25% of defecations will not be eligible for participation.
- •Less than 3 CSBMs per week at baseline and during pretreatment
- •Completed a colonoscopy in accordance with medical guidelines as appropriate, with no clinically significant findings
- •Patient is willing to discontinue use of supplemental fiber, laxatives, prescription and nonprescription medications, herbal or dietary supplements intended to treat constipation during the screening, pre-treatment, treatment and 2-week post-treatment periods
- •Willing to maintain a stable diet during the study.
- •Patients with hemorrhoids and/or diverticulosis (NOT diverticulitis) CAN be entered into the study.
Exclusion Criteria
- •Loose stool (mushy) or watery (Bristol score- 6 or 7) stool in the absence of any laxative or prohibited medicine for > 25% of BMs during the 3 months prior to screening visit OR during the 14 day treatment period
- •Patient meets the Rome III criteria for Irritable Bowel Syndrome (IBS-C)
- •Active peptic ulcer disease not adequately treated or not stable
- •History of cathartic colon, laxative, enema abuse, or ischemic colitis.
- •Fecal impaction within 3 months of screening
- •Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
- •Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis.
- •Major surgery within 60 days of screening.
Arms & Interventions
plecanatide 0.3 mg
Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
Intervention: plecanatide (Drug)
plecanatide 1.0 mg
Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
Intervention: plecanatide (Drug)
plecanatide 3.0 mg
Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
Intervention: plecanatide (Drug)
Placebo
Subjects receive placebo for 12 consecutive weeks
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
Overall Responder 9/12 Weeks
Time Frame: 12-Week Treatment Period
A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation. A weekly responder will have 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week. An overall responder is a patient who is a weekly responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks.
Secondary Outcomes
- Change From Baseline in 12-week CSBM Weekly Frequency Rate(12-Week Treatment Period)
- Change From Baseline in 12-week SBM Weekly Frequency Rate(12-Week Treatment Period)
- Change From Baseline in Stool Consistency (BSFS) to Over Treatment Period(12-Week Treatment Period)
- Change From Baseline in 12-week Patient Reported Symptoms Associated With Constipation - Straining Score(12-Week Treatment Period)